New imaging agent could revolutionize prostate cancer treatment monitoring

NCT ID NCT05155046

Recruiting now Diagnosis Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Apr 18, 2026 · Last updated Apr 29, 2026 · Updated 1 time

Summary

This study tests whether a special imaging agent called 18F-DCFPyL, used during PET scans, can better detect how prostate cancer responds to standard radiation therapy. About 130 adults with newly diagnosed, localized prostate cancer will receive PET/CT scans before and after treatment. The goal is to improve doctors' ability to see if the cancer is shrinking or spreading, which could lead to more personalized care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALIZED PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.

LOCALIZED PROSTATE CANCER